JP5698905B2 - 一酸化窒素の送達のための方法 - Google Patents

一酸化窒素の送達のための方法 Download PDF

Info

Publication number
JP5698905B2
JP5698905B2 JP2009512098A JP2009512098A JP5698905B2 JP 5698905 B2 JP5698905 B2 JP 5698905B2 JP 2009512098 A JP2009512098 A JP 2009512098A JP 2009512098 A JP2009512098 A JP 2009512098A JP 5698905 B2 JP5698905 B2 JP 5698905B2
Authority
JP
Japan
Prior art keywords
nox
protein
nox protein
item
tengcongensis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009512098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538133A (ja
JP2009538133A5 (enExample
Inventor
スティーブン ピー． エル． キャリー，
スティーブン ピー． エル． キャリー，
エリザベス エム． ブーン，
エリザベス エム． ブーン，
ジョナサン エー． ウィンガー，
ジョナサン エー． ウィンガー，
マイケル エー． マーレッタ，
マイケル エー． マーレッタ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2009538133A publication Critical patent/JP2009538133A/ja
Publication of JP2009538133A5 publication Critical patent/JP2009538133A5/ja
Application granted granted Critical
Publication of JP5698905B2 publication Critical patent/JP5698905B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/102499—Blood gas standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009512098A 2006-05-22 2007-05-21 一酸化窒素の送達のための方法 Active JP5698905B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92150506P 2006-05-22 2006-05-22
US60/921,505 2006-05-22
PCT/US2007/012133 WO2007139767A2 (en) 2006-05-22 2007-05-21 Compositions and methods for the delivery of nitric oxide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014180132A Division JP6118296B2 (ja) 2006-05-22 2014-09-04 一酸化窒素の送達のための方法

Publications (3)

Publication Number Publication Date
JP2009538133A JP2009538133A (ja) 2009-11-05
JP2009538133A5 JP2009538133A5 (enExample) 2010-07-08
JP5698905B2 true JP5698905B2 (ja) 2015-04-08

Family

ID=38779160

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009512098A Active JP5698905B2 (ja) 2006-05-22 2007-05-21 一酸化窒素の送達のための方法
JP2009512107A Active JP5698906B2 (ja) 2006-05-22 2007-05-21 一酸化窒素の送達のための組成物および方法
JP2014180140A Active JP6118772B2 (ja) 2006-05-22 2014-09-04 一酸化窒素の送達のための組成物および方法
JP2014180132A Active JP6118296B2 (ja) 2006-05-22 2014-09-04 一酸化窒素の送達のための方法
JP2017061455A Active JP6458070B2 (ja) 2006-05-22 2017-03-27 一酸化窒素の送達のための組成物および方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2009512107A Active JP5698906B2 (ja) 2006-05-22 2007-05-21 一酸化窒素の送達のための組成物および方法
JP2014180140A Active JP6118772B2 (ja) 2006-05-22 2014-09-04 一酸化窒素の送達のための組成物および方法
JP2014180132A Active JP6118296B2 (ja) 2006-05-22 2014-09-04 一酸化窒素の送達のための方法
JP2017061455A Active JP6458070B2 (ja) 2006-05-22 2017-03-27 一酸化窒素の送達のための組成物および方法

Country Status (12)

Country Link
US (7) US8404631B2 (enExample)
EP (7) EP2463294B1 (enExample)
JP (5) JP5698905B2 (enExample)
CN (5) CN106075388B (enExample)
AU (2) AU2007268028B2 (enExample)
BR (2) BRPI0711767B8 (enExample)
CA (2) CA2653101C (enExample)
DK (4) DK2040740T3 (enExample)
ES (4) ES2610653T3 (enExample)
IN (2) IN2013MN00601A (enExample)
NZ (4) NZ573004A (enExample)
WO (2) WO2007139767A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2463294B1 (en) 2006-05-22 2016-10-19 The Regents of The University of California Compositions and methods for the delivery of nitric oxide
US20110243849A1 (en) * 2010-04-02 2011-10-06 Marletta Michael A Heme-binding photoactive polypeptides and methods of use thereof
CA2897018C (en) * 2013-01-07 2021-07-27 Omniox, Inc. Polymeric forms of h-nox proteins
JP7049832B2 (ja) 2015-03-17 2022-04-07 オムニオクス， インコーポレイテッド タンパク質媒介性ｏ２送達による腫瘍免疫のモジュレーション
SG10202007517TA (en) * 2016-02-16 2020-09-29 Omniox Inc Modulation of hypoxia associated with stroke
JP6467073B2 (ja) * 2018-01-04 2019-02-06 オムニオクス， インコーポレイテッド Ｈ−ｎｏｘタンパク質の重合体形態
EP3836911A1 (en) 2018-08-15 2021-06-23 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
NZ783169A (en) 2019-06-25 2024-12-20 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
US20210147568A1 (en) 2019-10-31 2021-05-20 Forty Seven, Inc. Anti-cd47 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
WO2021222522A1 (en) 2020-05-01 2021-11-04 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240091056A (ko) 2021-10-28 2024-06-21 길리애드 사이언시즈, 인코포레이티드 피리디진-3(2h)-온 유도체
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
JP2024545193A (ja) 2021-12-22 2024-12-05 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US12358887B2 (en) 2022-03-17 2025-07-15 Gilead Sciences, Inc. IKAROS Zinc Finger Family degraders and uses thereof
KR20240165995A (ko) 2022-03-24 2024-11-25 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암의 치료를 위한 병용요법
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CN119487038A (zh) 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6022849A (en) 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US5731454A (en) 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
AU6766994A (en) 1994-04-01 1995-10-23 Unisyn Technologies, Inc. Culture media additives for hollow fiber bioreactors
AU735799C (en) * 1997-02-28 2005-04-28 Regents Of The University Of California, The Methods and compositions for optimisation of oxygen transport by cell-free systems
US6455676B1 (en) 1997-05-02 2002-09-24 Baxter Biotech Technology Sarl Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
US6773613B1 (en) 1998-10-15 2004-08-10 Sangart, Inc. Method for production of stroma-free hemoglobin
PL356815A1 (en) * 1999-12-22 2004-07-12 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors
EP1294868A2 (en) 2000-06-29 2003-03-26 Incyte Genomics, Inc. Adenylyl and guanylyl cyclases
US20030096240A1 (en) * 2000-09-19 2003-05-22 Ferid Murad Genomic organization of mouse and human sGC
US6780849B2 (en) * 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
CN1660100A (zh) * 2002-12-09 2005-08-31 上海倍艺医药科技有限公司 一种治疗糖尿病及其并发症的药物
EP2463294B1 (en) 2006-05-22 2016-10-19 The Regents of The University of California Compositions and methods for the delivery of nitric oxide

Also Published As

Publication number Publication date
WO2007139767A2 (en) 2007-12-06
BRPI0711767B8 (pt) 2021-05-25
NZ573003A (en) 2012-06-29
US10202428B2 (en) 2019-02-12
ES2610653T3 (es) 2017-04-28
JP2017137337A (ja) 2017-08-10
JP6118296B2 (ja) 2017-04-19
US20150376250A1 (en) 2015-12-31
ES2399662T3 (es) 2013-04-02
EP2463295A1 (en) 2012-06-13
JP6458070B2 (ja) 2019-01-23
US20130288970A1 (en) 2013-10-31
CN106075388B (zh) 2021-06-29
DK2463294T3 (en) 2017-01-16
CN101495506A (zh) 2009-07-29
JP2015007108A (ja) 2015-01-15
JP2009538134A (ja) 2009-11-05
JP2009538133A (ja) 2009-11-05
CN101495506B (zh) 2016-08-10
EP2040740B1 (en) 2014-09-03
IN2013MN00600A (enExample) 2015-06-12
US9493526B2 (en) 2016-11-15
CN106075388A (zh) 2016-11-09
EP2040740A2 (en) 2009-04-01
BRPI0711767B1 (pt) 2018-05-15
CA2653080A1 (en) 2007-12-06
US20150266931A1 (en) 2015-09-24
CN108273040A (zh) 2018-07-13
US20100285104A1 (en) 2010-11-11
CN101495134B (zh) 2016-08-03
EP2032156B1 (en) 2012-11-21
CA2653101A1 (en) 2007-12-06
DK2463297T3 (en) 2017-01-09
JP5698906B2 (ja) 2015-04-08
EP2032156A2 (en) 2009-03-11
CN104689300B (zh) 2018-06-05
US8404631B2 (en) 2013-03-26
EP2463294B1 (en) 2016-10-19
DK2032156T3 (da) 2013-02-18
US20170267732A1 (en) 2017-09-21
BRPI0711901A2 (pt) 2012-03-06
CA2653101C (en) 2016-12-13
US20100266673A1 (en) 2010-10-21
EP2463294A1 (en) 2012-06-13
CN104689300A (zh) 2015-06-10
JP2014224156A (ja) 2014-12-04
BRPI0711767A2 (pt) 2012-01-10
NZ594457A (en) 2013-06-28
NZ573004A (en) 2012-06-29
AU2007268052A1 (en) 2007-12-06
IN2013MN00601A (enExample) 2015-06-12
AU2007268028A1 (en) 2007-12-06
ES2611157T3 (es) 2017-05-05
EP2474554A2 (en) 2012-07-11
ES2525226T3 (es) 2014-12-19
AU2007268052B2 (en) 2013-07-04
HK1129688A1 (en) 2009-12-04
DK2040740T3 (en) 2014-12-01
CN101495134A (zh) 2009-07-29
EP2474554A3 (en) 2012-10-03
NZ594456A (en) 2013-06-28
WO2007139791A3 (en) 2008-05-02
EP2463297B1 (en) 2016-10-19
WO2007139767A3 (en) 2008-02-07
US9493527B2 (en) 2016-11-15
CA2653080C (en) 2019-02-12
US8404632B2 (en) 2013-03-26
US20130289252A1 (en) 2013-10-31
EP2463296A1 (en) 2012-06-13
EP2463297A1 (en) 2012-06-13
AU2007268028B2 (en) 2013-03-14
WO2007139791A2 (en) 2007-12-06
EP2040740A4 (en) 2009-10-21
JP6118772B2 (ja) 2017-04-19
EP2032156A4 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
JP5698905B2 (ja) 一酸化窒素の送達のための方法
AU2013201114B2 (en) Compositions and Methods for the Delivery of Nitric Oxide
HK1172038A (en) Compositions and methods for the delivery of nitric oxide
HK1130265A (en) Compositions and methods for the delivery of nitric oxide
HK1130265B (en) Compositions and methods for the delivery of nitric oxide
HK1137332A (en) Compositions and methods for the delivery of nitric oxide
HK1129688B (en) Compositions and methods for the delivery of oxygen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150216

R150 Certificate of patent or registration of utility model

Ref document number: 5698905

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250